An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

Moderna's financial challenges are compounded by a slowing adoption of its second product, the RSV vaccine, and an experimental cytomegalovirus (CMV) vaccine that has yet to meet early efficacy ...

The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology. Its mRNA technology could allow the firm to compete in a wide range of ...

Moderna has also filed for approval for a combination Covid-flu shot. And the company anticipates efficacy data this year from late-stage studies of vaccines for seasonal flu and norovirus ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt ...

Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

Next-generation COVID-19 vaccine: Moderna shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283) at its 2024 R&D Day event.